UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS Journal
Overview
publication venue for
- Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience. 42:2910000000000000.0-2.91e+27. 2024
- REAL-WORLD ELIGIBILITY AND UTILIZATION OF AVELUMAB MAINTENANCE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA 2024
- A multi-institutional study of 1,111 men with 4K score, multiparametric magnetic resonance imaging, and prostate biopsy. 41. 2023
- Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility. 41:3.57e+13-3.57e+23. 2023
- The "male lumpectomy": Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. 26:500-505. 2008
- Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapy. 26:506-510. 2008
- Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. 25:46-52. 2007
- Renal cell carcinoma (RCC) and telomerase activity: relationship to stage. 21:424-430. 2003
Research
category
- ONCOLOGY Web of Science Category
- UROLOGY & NEPHROLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 1078-1439
Electronic International Standard Serial Number (EISSN)
- 1873-2496
Other
journal abbreviation
- UROL ONCOL-SEMIN ORI